Mermoud A, Salmon J F, Alexander P, Straker C, Murray A D
Ophthalmology Department, Groote Schuur Hospital, Cape Town, South Africa.
Ophthalmology. 1993 Jun;100(6):897-902.
The Molteno implant has been shown to be useful in the treatment of neovascular glaucoma. However, a wide range of success rates has been reported. This is related to the use of differing criteria for success, varying periods of follow-up, and difficulty in quantifying the preoperative condition of the eye.
The authors studied the long-term results of the Molteno single-plate implant in 60 eyes with neovascular glaucoma using Kaplan-Meier life-table analysis. Age, visual acuity, underlying retinal diseases, and preoperative retinal ablation treatment were evaluated to establish factors influencing the surgical outcome. The criteria for success included a postoperative intraocular pressure (IOP) of less than or equal to 21 mmHg and maintenance of vision.
The success rate was 62.1% at 1 year, 52.9% at 2 years, 43.1% at 3 years, 30.8% at 4 years, and 10.3% at 5 years. The main causes for failure were loss of light perception in 48% of eyes (29/60), progression to phthisis bulbi in 18% (11/60), and encapsulation of the filtering bleb in 10% (6/60). The long-term surgical outcome was significantly better in patients older than 55 years of age (P = 0.048) and in those with a preoperative visual acuity equal to or better than 6/60 (P = 0.019). Eyes with neovascular glaucoma secondary to diabetic retinopathy had a better prognosis than those with a central retinal vein occlusion (P = 0.003).
Although the IOP can be significantly reduced after Molteno implantation, this study suggests that in severely compromised eyes with neovascular glaucoma the main advantage of Molteno implantation is pain relief and avoidance of enucleation.
已证明莫尔滕诺植入物在新生血管性青光眼的治疗中有用。然而,报告的成功率范围很广。这与使用不同的成功标准、不同的随访期以及难以量化术前眼部状况有关。
作者使用Kaplan-Meier生存表分析研究了莫尔滕诺单板植入物在60只新生血管性青光眼眼中的长期结果。评估年龄、视力、潜在的视网膜疾病和术前视网膜光凝治疗,以确定影响手术结果的因素。成功标准包括术后眼压(IOP)小于或等于21 mmHg以及视力维持。
1年时成功率为62.1%,2年时为52.9%,3年时为43.1%,4年时为30.8%,5年时为10.3%。失败的主要原因是48%的眼睛(29/60)失去光感,18%(11/60)进展为眼球痨,10%(6/60)滤过泡包囊形成。55岁以上患者(P = 0.048)和术前视力等于或优于6/60的患者(P = 0.019)的长期手术结果明显更好。糖尿病性视网膜病变继发的新生血管性青光眼眼的预后比视网膜中央静脉阻塞继发的眼更好(P = 0.003)。
尽管莫尔滕诺植入术后眼压可显著降低,但本研究表明,对于严重受损的新生血管性青光眼眼,莫尔滕诺植入的主要优势是缓解疼痛和避免眼球摘除。